Why the study?
Does intravenous recombinant human tissue-type plasminogen activator reduce the persistence of unstable angina and subocclusive thrombus in patients with unstable angina pectoris?
Population
24 patients with unstable angina pectoris, defined as chest pain at rest with transient ST segment deviation…
Comparison
Intravenous recombinant human tissue-type… vs Blinded placebo. Both groups received background…
Design
RCT, randomly assigned, blinded, placebo-controlled
Follow-up
7 +/- 5 days (placebo) and 8 +/- 4 days (rt-PA)
Authors
Loading...
Supports rt-PA for unstable angina with thrombus; extends randomized evidence for thrombolysis in non–ST-elevation syndromes.
Does intravenous recombinant human tissue-type plasminogen activator reduce the persistence of unstable angina and subocclusive thrombus in patients with unstable angina pectoris?
Intravenous rt-PA significantly reduced the persistence of unstable angina and the presence of subocclusive thrombus compared to placebo in patients with unstable angina.
Gold et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: